Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder (HDQ)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Manhattan Psychiatric Center.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Nathan Kline Institute for Psychiatric Research
Information provided by:
Manhattan Psychiatric Center
ClinicalTrials.gov Identifier:
NCT00297947
First received: February 27, 2006
Last updated: July 28, 2011
Last verified: August 2010
  Purpose

This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.


Condition Intervention Phase
Schizophrenia
Schizoaffective Disorder
Drug: quetiapine
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder

Resource links provided by NLM:


Further study details as provided by Manhattan Psychiatric Center:

Primary Outcome Measures:
  • To see if mean extrapyramidal symptoms measure will change significantly from baseline to endpoint for the whole group and if the mean change in EPS measure is significantly different between quetiapine 1200mg daily group and quetiapine 600mg daily group [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To see if treatment with quetiapine 1200 mg per day will improve total PANSS more robustly than quetiapine 600 mg per day [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: December 2004
Estimated Study Completion Date: December 2012
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 600 mg/day quetiapine (Group B) Drug: quetiapine
Participant will receive 600 mg/day of quetiapine for 8 weeks.
Other Name: Seroquel
Experimental: 1200 mg/day quetiapine (Group A) Drug: quetiapine
Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
Other Name: Seroquel

Detailed Description:

The study will be conducted at two sites: Manhattan Psychiatric Center (MPC), and the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research/Rockland Psychiatric Center (NKI). A total of 60 patients will be enrolled, 30 at each location. After a screening period of 1 week, all patients will be entering an open label, four-week quetiapine treatment period (run-in phase), during which quetiapine will be titrated to 600 mg PO daily and other adjunctive antipsychotics will be gradually tapered and discontinued. Other concomitant medications such as mood stabilizers will be maintained, if their dose has been stable for the preceding 2 months. Patients not responding to quetiapine treatment at 600 mg PO (defined as reduction of < 15% change in Positive and Negative Syndrome Scale (PANSS) total score between start of run-in to end of week 4) during the run-in phase, will be eligible to enter the double blind phase. Study baseline will be Day 7 of Week 4 of the run-in phase. Patients qualifying for the double-blind phase will be randomly assigned to either high dose 1200 mg quetiapine daily (Group A) or to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double blind fashion for 8 weeks (Week 1 through Week 8 of double blind phase). Measures of extra-pyramidal side effects, psychopathology, and safety will be conducted throughout the trial.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. DSM-IV criteria for chronic schizophrenia or schizoaffective disorder
  2. Sub-optimal treatment-response
  3. Total score > 60 on the Positive and Negative Syndrome Scale (PANSS) at baseline of run-in phase and again at baseline of double blind phase
  4. Age 18-64 years old
  5. Signed informed consent
  6. Patient is in good general medical health

Exclusion criteria:

  1. History of failure to respond to 400 mg/day or more of clozapine for 8 contiguous weeks
  2. History of failure to respond to quetiapine treatment at dosages > 1200 mg daily for 6 contiguous weeks
  3. History of quetiapine intolerance (e.g., clinically significant leukopenia or agranulocytosis, or severe dystonic reactions)
  4. Significant recent history of violence or suicidal activity, which required > 4 episodes of PRN anti-agitation medication per week
  5. Mental retardation
  6. Depot antipsychotic within 30 days before randomization
  7. Significant medical illness requiring frequent dose adjustment or medication changes

Clozapine non-responders are explicitly excluded, as they would be unlikely to show a response in this study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00297947

Locations
United States, New York
Manhattan Psychiatric Center
New York, New York, United States, 10035
Nathan Kline Institute for Psychiatric Research
Orangeburg, New York, United States, 10962
Sponsors and Collaborators
Manhattan Psychiatric Center
Nathan Kline Institute for Psychiatric Research
Investigators
Principal Investigator: Jean-Pierre Lindenmayer, MD Manhattan Psychiatric Center
Principal Investigator: Leslie Citrome, MD Nathan Kline Institute for Psychiatric Research
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jean-Pierre Lindenmayer, Manhattan Psychiatric Center
ClinicalTrials.gov Identifier: NCT00297947     History of Changes
Other Study ID Numbers: IRUSQUET0348
Study First Received: February 27, 2006
Last Updated: July 28, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Manhattan Psychiatric Center:
schizophrenia
quetiapine
schizoaffective disorder

Additional relevant MeSH terms:
Disease
Psychotic Disorders
Schizophrenia
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Quetiapine
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 24, 2014